Recurrence of primary sclerosing cholangitis

What do we learn from several transplant centers?

Phunchai Charatcharoenwitthaya, Keith Lindor

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

In summary, recurrent PSC is now established as an important clinical outcome after liver transplantation. Over time, this problem is likely to increase and exert more impact on patient and graft survival. Thus, further large-scale longitudinal multicenter studies will be necessary to assess the impact of recurrent PSC on long-term outcomes. The mechanism for recurrent PSC is unknown, but current data lend support to an association with rejection and corticosteroid therapy in susceptible patients. With respect to this growing problem, several critical questions can be posed as priorities for researchers in the future. What effect will novel immunosuppressive medications or rapid corticosteroid withdrawal protocols have on the incidence and severity of recurrent disease? Which patients are more likely to develop recurrence? What medication should be administered as preventive therapy for recurrence? Understanding the pathogenesis of the disease is a key to answering these questions.

Original languageEnglish (US)
Pages (from-to)130-132
Number of pages3
JournalLiver Transplantation
Volume14
Issue number2
DOIs
StatePublished - Feb 2008
Externally publishedYes

Fingerprint

Sclerosing Cholangitis
Transplants
Recurrence
Adrenal Cortex Hormones
Graft Survival
Immunosuppressive Agents
Liver Transplantation
Multicenter Studies
Longitudinal Studies
Research Personnel
Incidence
Therapeutics

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Recurrence of primary sclerosing cholangitis : What do we learn from several transplant centers? / Charatcharoenwitthaya, Phunchai; Lindor, Keith.

In: Liver Transplantation, Vol. 14, No. 2, 02.2008, p. 130-132.

Research output: Contribution to journalArticle

@article{ee075e0bc9b64e69b0d0b7b046c192c4,
title = "Recurrence of primary sclerosing cholangitis: What do we learn from several transplant centers?",
abstract = "In summary, recurrent PSC is now established as an important clinical outcome after liver transplantation. Over time, this problem is likely to increase and exert more impact on patient and graft survival. Thus, further large-scale longitudinal multicenter studies will be necessary to assess the impact of recurrent PSC on long-term outcomes. The mechanism for recurrent PSC is unknown, but current data lend support to an association with rejection and corticosteroid therapy in susceptible patients. With respect to this growing problem, several critical questions can be posed as priorities for researchers in the future. What effect will novel immunosuppressive medications or rapid corticosteroid withdrawal protocols have on the incidence and severity of recurrent disease? Which patients are more likely to develop recurrence? What medication should be administered as preventive therapy for recurrence? Understanding the pathogenesis of the disease is a key to answering these questions.",
author = "Phunchai Charatcharoenwitthaya and Keith Lindor",
year = "2008",
month = "2",
doi = "10.1002/lt.21403",
language = "English (US)",
volume = "14",
pages = "130--132",
journal = "Liver Transplantation",
issn = "1527-6465",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Recurrence of primary sclerosing cholangitis

T2 - What do we learn from several transplant centers?

AU - Charatcharoenwitthaya, Phunchai

AU - Lindor, Keith

PY - 2008/2

Y1 - 2008/2

N2 - In summary, recurrent PSC is now established as an important clinical outcome after liver transplantation. Over time, this problem is likely to increase and exert more impact on patient and graft survival. Thus, further large-scale longitudinal multicenter studies will be necessary to assess the impact of recurrent PSC on long-term outcomes. The mechanism for recurrent PSC is unknown, but current data lend support to an association with rejection and corticosteroid therapy in susceptible patients. With respect to this growing problem, several critical questions can be posed as priorities for researchers in the future. What effect will novel immunosuppressive medications or rapid corticosteroid withdrawal protocols have on the incidence and severity of recurrent disease? Which patients are more likely to develop recurrence? What medication should be administered as preventive therapy for recurrence? Understanding the pathogenesis of the disease is a key to answering these questions.

AB - In summary, recurrent PSC is now established as an important clinical outcome after liver transplantation. Over time, this problem is likely to increase and exert more impact on patient and graft survival. Thus, further large-scale longitudinal multicenter studies will be necessary to assess the impact of recurrent PSC on long-term outcomes. The mechanism for recurrent PSC is unknown, but current data lend support to an association with rejection and corticosteroid therapy in susceptible patients. With respect to this growing problem, several critical questions can be posed as priorities for researchers in the future. What effect will novel immunosuppressive medications or rapid corticosteroid withdrawal protocols have on the incidence and severity of recurrent disease? Which patients are more likely to develop recurrence? What medication should be administered as preventive therapy for recurrence? Understanding the pathogenesis of the disease is a key to answering these questions.

UR - http://www.scopus.com/inward/record.url?scp=39449128279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39449128279&partnerID=8YFLogxK

U2 - 10.1002/lt.21403

DO - 10.1002/lt.21403

M3 - Article

VL - 14

SP - 130

EP - 132

JO - Liver Transplantation

JF - Liver Transplantation

SN - 1527-6465

IS - 2

ER -